A bispecific single domain antibody boosts autologous V γ9Vδ2-T cell responses towards CD1d in chronic lymphocytic leukemia.

CONCLUSION: Collectively, our data demonstrate the immunotherapeutic potential of this novel CD1d-specific Vγ9Vδ2-T cell engager in CLL.
PMID: 33451981 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 15, 2021 Category: Cancer & Oncology Authors: de Weerdt I, Lameris R, Ruben JM, de Boer R, Kloosterman J, King LA, Levin MD, Parren PWHI, de Gruijl TD, Kater AP, van der Vliet HJ Tags: Clin Cancer Res Source Type: research